Eagle Pharmaceuticals, Inc. (EGRX)

Market Cap	8.47M
Revenue (ttm)	257.55M
Net Income (ttm)	11.95M
Shares Out	13.02M
EPS (ttm)	0.91
PE Ratio	0.71
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	18,609
Open	0.824
Previous Close	0.701
Day's Range	0.650 - 0.824
52-Week Range	0.220 - 9.350
Beta	0.52
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 8, 2024

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2007
• Employees: 134
• Stock Exchange: OTCMKTS
• Ticker Symbol: EGRX